ArcherDX Enters Collaboration with Bristol Myers Squibb to Apply Personalized Cancer Monitoring (PCM™) to Clinical Research
By: Colorado BioScience Association Date: 06/18/2020
Aims to Inform use of Minimal Residual Disease (MRD) Monitoring in Clinical Trial Protocols and Future Therapy Optimization
BOULDER, Colo., June 18, 2020 /PRNewswire/ – ArcherDX, Inc. today announced it is entering into a collaboration with Bristol Myers Squibb (BMS) to utilize Personalized Cancer Monitoring (PCM™) assays to understand the potential benefits of minimal residual disease (MRD) detection in cancer patients treated with immunotherapy. PCM provides tumor-informed longitudinal analysis of circulating tumor DNA (ctDNA) found in patient blood where the quantity of ctDNA is a predictor of disease stage and burden, and achieves accuracy at low limits of detection by focusing the ctDNA analysis on known patient-specific mutations found in the tumor tissue.[i] ArcherDX and BMS will evaluate the clinical samples from cancer patient cohorts with the goal of advancing the use of MRD detection or ctDNA clearance to potentially inform future therapy selection and/or optimization.
“Collaborating with BMS, a leader in oncology, is a significant step toward accomplishing our common goal of improving patient outcomes. We are delighted BMS chose to leverage our Personalized Cancer Monitoring assays for clinical research aimed at expanding precision oncology into early-stage cancers, when the cancer is typically easier to cure compared to late-stage cancers,” said Jason Myers, Chief Executive Officer and co-founder of ArcherDX. “This collaboration further underscores our intention to facilitate real-time monitoring of ctDNA during and after therapy with personalized, decentralized assays that can be distributed across the globe and could potentially optimize the use of current and future cancer therapies.”
Find out more in the press release.